Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Seidensticker, Max ^a,b   Seidensticker, Ricarda ^a,b   Damm, Robert ^a,b   Mohnike, Konrad ^a,b   Pech, Maciej ^a,b,g   Sangro, Bruno ^c   Hass, Peter ^d   Wust, Peter ^e   Kropf, Siegfried ^f   Gademann, Günther ^d   Ricke, Jens ^a,b  

^a Klinik fur Radiologie und Nuklearmedizin   (Germany)

^b Deutsche Akademie für Mikrotherapie International School of Image Guided Interventions   (Germany)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d Univ Klin fur Strahlentherapie   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f Inst fur Biometrie und Med Info   (Germany)

^g MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; GADOXETIC ACID; IODINATED CONTRAST MEDIUM; PENTOXIFYLLINE; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSIMETRY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMAGE GUIDED INTERSTITIAL BRACHYTHERAPY; IMAGE GUIDED RADIOTHERAPY; LIVER METASTASIS; LIVER TOXICITY; LOW DRUG DOSE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ADVERSE EFFECTS; CLINICAL TRIAL; COLORECTAL NEOPLASMS; LIVER NEOPLASMS; METASTASIS; MIDDLE AGED; PROCEDURES; RADIATION INJURIES; SECONDARY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COLORECTAL NEOPLASMS; ENOXAPARIN; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PENTOXIFYLLINE; PROSPECTIVE STUDIES; RADIATION INJURIES; URSODEOXYCHOLIC ACID;

EID: 84911494298     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112731     Document Type: Article

References (39)

1. Boda-Heggemann J, Dinter D, Weiss C, Frauenfeld A, Siebenlist K, et al. (2012) Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases-clinical results. Radiation oncology 7: 92.
2. Ricke J, Mohnike K, Pech M, Seidensticker M, Ruhl R, et al. (2010) Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. International journal of radiation oncology, biology, physics 78: 479-485.
3. Seidensticker R, Denecke T, Kraus P, Seidensticker M, Mohnike K, et al. (2012) Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovascular and interventional radiology 35: 1066-1073.
4. Emami B, Lyman J, Brown A, Coia L, Goitein M, et al. (1991) Tolerance of normal tissue to therapeutic irradiation. International journal of radiation oncology, biology, physics 21: 109-122.
5. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, et al. (1995) Hepatic toxicity resulting from cancer treatment. International journal of radiation oncology, biology, physics 31: 1237-1248.
6. Ricke J, Seidensticker M, Ludemann L, Pech M, Wieners G, et al. (2005) In vivo assessment of the tolerance dose of small liver volumes after single-fraction HDR irradiation. International journal of radiation oncology, biology, physics 62: 776-784.
7. Seidensticker M, Seidensticker R, Mohnike K, Wybranski C, Kalinski T, et al. (2011) Quantitative in vivo assessment of radiation injury of the liver using Gd-EOB-DTPA enhanced MRI: tolerance dose of small liver volumes. Radiation oncology 6: 40.
8. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED (1985) The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation 39: 603-608.
9. Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, et al. (2008) Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112: 1538-1546.
10. Farthing MJ, Clark ML, Sloane JP, Powles RL, McElwain TJ (1982) Liver disease after bone marrow transplantation. Gut 23: 465-474.
11. Fajardo LF, Colby TV (1980) Pathogenesis of veno-occlusive liver disease after radiation. Archives of pathology & laboratory medicine 104: 584-588.
12. Reed GB, Jr., Cox AJ, Jr (1966) The human liver after radiation injury. A form of veno-occlusive disease. The American journal of pathology 48: 597-611.
13. Shulman HM, Gown AM, Nugent DJ (1987) Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. The American journal of pathology 127: 549-558.
14. Attal M, Huguet F, Rubie H, Charlet JP, Schlaifer D, et al. (1993) Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 82: 732-736.
15. Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, et al. (1992) Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 79: 2834-2840.
16. Bianco JA, Appelbaum FR, Nemunaitis J, Almgren J, Andrews F, et al. (1991) Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 78: 1205-1211.
17. Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, et al. (1998) Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Annals of internal medicine 128: 975-981.
18. Forrest DL, Thompson K, Dorcas VG, Couban SH, Pierce R (2003) Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Bone marrow transplantation 31: 1143-1149.
19. Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, et al. (2000) The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. American journal of hematology 64: 32-38.
20. Or R, Nagler A, Shpilberg O, Elad S, Naparstek E, et al. (1996) Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 61: 1067-1071.
21. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, et al. (2002) Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 100: 1977-1983.
22. Clift RA, Bianco JA, Appelbaum FR, Buckner CD, Singer JW, et al. (1993) A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 82: 2025-2030.
23. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED (1984) Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4: 116-122.
24. Seidensticker M, Burak M, Kalinski T, Garlipp B, Koelble K, et al. (2014) Radiation-Induced Liver Damage: Correlation of Histopathology with Hepatobiliary Magnetic Resonance Imaging, a Feasibility Study. Cardiovascular and interventional radiology.
25. Wybranski C, Seidensticker M, Mohnike K, Kropf S, Wust P, et al. (2009) In vivo assessment of dose volume and dose gradient effects on the tolerance dose of small liver volumes after single-fraction high-dose-rate 192Ir irradiation. Radiation research 172: 598-606.
26. Shulman HM, Hinterberger W (1992) Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone marrow transplantation 10: 197-214.
27. Lakshminarayanan S, Sahdev I, Goyal M, Vlachos A, Atlas M, et al. (2010) Low incidence of hepatic veno-occlusive disease in pediatric patients undergoing hematopoietic stem cell transplantation attributed to a combination of intravenous heparin, oral glutamine, and ursodiol at a single transplant institution. Pediatric transplantation 14: 618-621.
28. Park SH, Lee MH, Lee H, Kim HS, Kim K, et al. (2002) A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone marrow transplantation 29: 137-143.
29. Lee JH, Lee KH, Kim S, Lee JS, Kim WK, et al. (1998) Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study. Bone marrow transplantation 22: 883-888.
30. Catani L, Gugliotta L, Vianelli N, Nocentini F, Baravelli S, et al. (1996) Endothelium and bone marrow transplantation. Bone marrow transplantation 17: 277-280.
31. Geraci JP, Mariano MS (1993) Radiation hepatology of the rat: parenchymal and nonparenchymal cell injury. Radiation research 136: 205-213.
32. Kowdley KV (2000) Ursodeoxycholic acid therapy in hepatobiliary disease. The American journal of medicine 108: 481-486.
33. Neuman MG, Shear NH, Bellentani S, Tiribelli C (1998) Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells. Gastroenterology 115: 157-166.
34. Lindner H, Holler E, Ertl B, Multhoff G, Schreglmann M, et al. (1997) Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and may prevent repair: role of cytokines. Blood 89: 1931-1938.
35. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ (1998) A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. The Journal of clinical investigation 101: 2790-2799.
36. Pascolo L, Cupelli F, Anelli PL, Lorusso V, Visigalli M, et al. (1999) Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents. Biochemical and biophysical research communications 257: 746-752.
37. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, et al. (1992) Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 183: 59-64.
38. Watanabe H, Kanematsu M, Goshima S, Kondo H, Onozuka M, et al. (2011) Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging-preliminary observations. Radiology 259: 142-150.
39. Shin NY, Kim MJ, Lim JS, Park MS, Chung YE, et al. (2012) Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. European radiology 22: 864-871.